Abbott Laboratories (ABT) 46.09 $ABT
SmarTrend Watching for Potential Pullback in Shares of Abbott Laboratories After 1.92% Gain
Comtex SmarTrend(R) - Fri Feb 13, 3:54PM CST
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $45.02 to a high of $46.17. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $45.25 on volume of 6.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ABT: 46.09 (+0.87)
3 Health Care Stocks On The Rise
at The Street - Fri Feb 13, 11:04AM CST
TheStreet highlights 3 stocks pushing the health care sector higher today.
ABT: 46.09 (+0.87), ALXN: 182.29 (+6.02), ABBV: 58.05 (+1.00)
$173 Billion Wearable Technology Market Report 2015-2020 - Analysis of 221 Companies Offering 132 Different Wearable Technology Products
M2 - Thu Feb 12, 6:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/pwzm38/wearable) has announced the addition of the "Wearable Technology: 2015" report to their offering. Wearable technology will be worth USD 22.7 billion in 2015 rising to USD 173.3 billion by 2020, but the long-term potential of the sector will make these numbers seem rather small. The wearable technology market currently contains the following product segments: body sensors, smart watches, smart glasses, personal video recorders, electronic apparel and jewellery. These products are being used for the following purposes: health and activity tracking, sports performance monitors, wearable web, healthcare, life logging, location tracking and fashion and protective apparel. All these segments are included in this report. The report includes forecasts from 2014 to 2020 for smart watches, smart glasses, fitness and activity trackers and sports performance monitors. You will find very clear and detailed explanations of these and a wide range of other segments of the wearable technology market - plus plenty of examples of companies and products that occupy each of these segments. This report also contains a detailed review and status report for the main enabling technologies that will take the wearables market to the next level: ECG, body power, multi-function earbuds, thought control, electronic contact lenses and bio sensors (ingestibles and implants). You will also be able to read a very clear and detailed analysis of the future direction of the wearable technology market which will see the sector evolve from a largely device-focused industry into something far larger and more exciting. Key Topics Covered: 1. Executive Summary 2. Introduction: Market Segmentation 3. Market Developments: Last 12 Months 4. Wearable Technology Company Profiles 5. Future: Important Enabling Technologies 6. Market Analysis 7. Two $1 Trillion Wearables Opportunities 8. Market Forecasts Companies Mentioned - Abbott Laboratories - Adidas - Apple Watch - Casio - Ezio - FiLIP Technologies - Fitbit - Fitbug - Garmin - Google - Huawei B1 TalkBand - Intel - Jawbone - LG - Lenovo - Medtronic - Microsoft - Misfit Wearables - Motorola Mobility - Nike - Nissan - Omega Wave - Pebble - Pivothead - Polar - Qualcomm - Samsung - Sony - TomTom For more information visit http://www.researchandmarkets.com/research/pwzm38/wearable
ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), QCOM: 70.88 (+0.49), GRMN: 55.93 (+0.02)
Global In-Vitro Diagnostics (IVD) Market Report: 2014 Edition
M2 - Wed Feb 11, 2:14PM CST
Research and Markets (http://www.researchandmarkets.com/research/62bj7n/global_invitro) has announced the addition of the "Global In-Vitro Diagnostics (IVD) Market Report: 2014 Edition" report to their offering. An in-vitro diagnostic test is performed outside of a human body in an artificial environment (e.g. laboratory). IVD is considered as an essential part of today's healthcare. The IVD products are broadly divided into three categories: reagents, analytical instruments and accessory products. IVD is widely used for diagnosis, monitoring of prescribed treatments and assessment of medical intervention, apart from others thereby contributing to availability of medical information regarding a patient. Furthermore, IVD allows earlier and more targeted treatment which in turn leads to reduced hospital stays and convalescences resulting in a healthier population and economic growth in the long run. The key factors which are anticipated to drive market growth include rising global healthcare expense, increasing global ageing population, accelerating global diabetic population apart from rising incidences of chronic and infectious diseases and increasing global gross national income. Some of the noteworthy developments of this industry include food safety testing market being taken over, development in patient monitoring and telemedicine, continued expansion of POC testing apart from mergers and acquisitions. However, the industry remains threatened by certain challenges which include lack of economies of scale and scope, increase in investment demands apart from usual regulatory, reimbursement and intellectual property issues. This report offers a comprehensive analysis of the global in-vitro diagnostic market, along with an in-depth study of the IVD segments and the regional markets of Europe and China. The global IVD industry is consolidated with the top players, Abbott, Siemens, Roche and Johnson and Johnson which operate in a highly competitive environment. The above mentioned companies are being profiled along with their key financials and strategies for growth. Key Topics Covered: 1. Overview 2. IVD Market Size 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Featured: - Abbott Laboratories - Siemens AG - Roche Holdings AG - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/62...al_invitro
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87)
Global Glucose Monitoring Market Report: 2015 Edition
M2 - Wed Feb 11, 10:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/q2z5b6/global_glucose) has announced the addition of the "Global Glucose Monitoring Market Report: 2015 Edition" report to their offering. The key factors which are anticipated to drive the market include factors like increasing aging population, rising healthcare expenditure, increasing urbanization, obese population and awareness about blood glucose monitoring. Some of the noteworthy developments of this industry include sedentary lifestyle, increasing prevalence of diabetes, among others. However, the growth of respective industry is hindered by the barriers of regulatory risk, intense competition, and non-invasive blood glucose monitoring, among others. This report offers a comprehensive analysis of the global glucose monitoring industry. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. On the contention front, the global glucose monitoring market is reined by few major players namely, Johnson and Johnson, Bayer, Roche and Abbott. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail. Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Featured: - Johnson and Johnson - Abbott Laboratories - Roche Holdings AG - Bayer AG For more information visit http://www.researchandmarkets.com/research/q2...al_glucose
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87)
Zoetis Beats on Q4 Earnings, Provides In-Line 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:56AM CST
Zoetis' fourth-quarter 2014 adjusted earnings of 40 cents per share were ahead of the Zacks Consensus Estimate.
ZTS: 45.46 (-0.33), ABT: 46.09 (+0.87), ALNY: 95.54 (+1.67), ACHN: 10.89 (-0.20)
Global Insulin Delivery Devices Market 2014-2018: Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co Account for 90% of Global Share
M2 - Wed Feb 11, 9:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/hjxrhm/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering. This study thus leads to the proposition that innovation has huge scope in the field of insulin delivery and its analysts have elaborate information on some of the emerging insulin delivery devices. Finally, an analysis of the leading market players provides a holistic understanding to the reader. Players covered include Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co. These players together account for more than 90% of the global market. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Global Insulin Market Overview to 2018 4. Industry Trends and Drivers 5. Key Market Restraints 6. Global Insulin Delivery Devices Market Outlook to 2018 7. Insulin Delivery Devices: Current and Future Outlook to 2018 8. Emerging Devices 9. Key Players - Abbott Laboratories - B. Braun Melsungen AG - Becton Dickinson - Eli Lilly - F. Hoffmann La Roche - Insulet Corporation - Johnson and Johnson - Medtronic - Novo Nordisk - Sanofi-Aventis - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/hj...al_insulin
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), PODD: 32.00 (-0.07), NVO: 43.76 (+0.61), MDT: 75.26 (+0.33), LLY: 70.56 (+0.03)
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Global Digital PCR (dPCR) Market 2015-2019: Key Vendors are Bio-Rad Laboratories, Fluidigm, RainDance Technologies & Thermo Fisher Scientific
M2 - Wed Feb 11, 6:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/gqxfbj/global_digital) has announced the addition of the "Global Digital PCR (dPCR) Market 2015-2019" report to their offering. The Global dPCR market to grow at a CAGR of 26.45% over the period 2014-2019 The dPCR technology is an innovative PCR that allows amplification and directs quantification of nucleic acids such as DNA, RNA, cDNA, and methylated DNA with high precision. The dPCR technology is not dependent on the number of amplification cycles to quantify the initial sample amount and provides absolute quantification of nucleic acids. dPCR can analyze a small amount of sample and provide higher accuracy, precision, and efficiency than the conventional PCR technology. The adoption of dPCR technology is a major trend upcoming in this market. Advanced dPCR technology and products provide a high degree of accuracy and productivity in research and drug discovery and reduce the consumption of reagents. According to the report, one of the major drivers of the market is advances in dPCR technology. dPCR technologies and products have improved because of automation, accuracy, sensitivity, and ease of handling. In addition, advanced dPCR products provide greater efficiency and productivity in research and drug discovery and help reduce the time taken for the development of new drugs. Further, the report states that availability of alternative technologies is a major challenge that the market faces. Availability of other sequencing technologies such as other PCR techniques and NGS poses a serious threat to the adoption of dPCR technology. The dPCR technologies have a broad range of applications in various fields including: - Drug discovery and development - Clinical diagnostics - Research - Others Key Vendors - Bio-Rad Laboratories - Fluidigm - RainDance Technologies - Thermo Fisher Scientific Other Prominent Vendors - Abbott Laboratories - Affymetrix - Analytik Jena - ArcticZymes - Becton Dickinson - Bibby Scientific - bioMerieux - Biosearch Technologies - BIOTECON Diagnostics - Eppendorf - Exiqon - Formulatrix - Illumina - Integrated DNA Technologies - Promega - Sigma-Aldrich - Stilla Technologies For more information visit http://www.researchandmarkets.com/research/gq...al_digital
ABT: 46.09 (+0.87)
Sports and Fitness Nutrition Supplements - Global Strategic Business Report 2015
M2 - Wed Feb 11, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/kzpfhr/sports_and) has announced the addition of the "Sports and Fitness Nutrition Supplements - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Sports and Fitness Nutrition Supplements in US$ Thousands by the following Segments: - Amino Acids/Derivatives - Herbal Products - Vitamins/Minerals - Others Company profiles are primarily based on public domain information including company URLs. The report profiles 237 companies including many key and niche players such as: - Abbott Laboratories Inc. (US) - Champion Nutrition, Inc. (US) - Clif Bar & Company (US) - Dymatize Enterprises, Inc. (US) - Glanbia Plc (Ireland) - Optimum Nutrition, Inc. (US) - GlaxoSmithKline Plc (UK) - GNC Holdings, Inc. (US) - Herbalife International, Inc. (US) - NBTY, Inc. (US) - The Balance Bar Company (US) - Nestl? SA (Switzerland) - Otsuka Pharmaceutical Co., Ltd. (Japan) - PepsiCo Inc. (US) - Red Bull GmbH (Austria) - The Coca-Cola Co. (US) - Yakult Honsha Co., Ltd. (Japan) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. MARKET DYNAMICS 3. TRENDS AND ISSUES 4. PRODUCT INNOVATIONS: A CLOSER LOOK 5. PRODUCT OVERVIEW 6. PRODUCT INTRODUCTIONS/LAUNCHES 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT GLOBAL PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 237 (including Divisions/Subsidiaries 253) - The United States (173) - Canada (9) - Japan (3) - Europe (48) - France (2) - Germany (2) - The United Kingdom (30) - Rest of Europe (14) - Asia-Pacific (Excluding Japan) (15) - Latin America (1) - Africa (4) For more information visit http://www.researchandmarkets.com/research/kzpfhr/sports_and
HLF: 32.78 (-0.84), ABT: 46.09 (+0.87), GSK: 47.94 (+1.99), PEP: 99.13 (-1.14)
Mylan Faces Patent Infringement Lawsuit for Nexavar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:02PM CST
Mylan (MYL) confirms patent challenge for generic version of Nexavar, and it expects exclusivity.
IPXL: 39.51 (+0.69), ABT: 46.09 (+0.87), MYL: 55.85 (+1.34)
Pfizer Pays A Pretty Penny For Hospira: Here's What You Need To Know
Brendan O'Boyle - at Seeking Alpha - Tue Feb 10, 8:49AM CST
ABT: 46.09 (+0.87), TARO: 161.14 (-1.44), PFE: 34.64 (-0.23), MYL: 55.85 (+1.34), EPRS: 7.67 (+0.67), TEVA: 56.77 (-0.58), HSP: 87.35 (unch)
Patient Monitoring Global Market 2015 - Forecast to 2020
M2 - Tue Feb 10, 8:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/vvvf8m/patient) has announced the addition of the "Patient Monitoring Global Market - Forecast to 2020" report to their offering. The global patient monitoring devices market is expected to reach approximately $24 billion by 2019 growing at CAGR of around 8.0%. North America commands the largest share and is expected to register a healthy market share by 2019. APAC is going to be one of the prominent regions for this market in coming years driven by the increased purchasing power and rising population. Patient monitoring is essential part of care process together with administration of therapy. The main aim of monitoring is to make sure that proper care [or] therapy can be given in advance to the arrival of complications. Patient monitoring is essential to take care in emergency and operating rooms, intensive and critical care units and it is extremely useful for recovery rooms, respiration therapy, radiology, outpatient care, and gastroenterology department, Transport, Home and sleep screening applications. Patient monitoring play key role to reduce complications, risks, infections as well assist in providing for patient comfort. Patient monitoring devices market is mainly divided into following segments such as Hemodynamic, neurology, respiratory, Cardiology, fetal and neonatal, multi parameters, remote patient monitors, temperature and weight monitors. Some of the key players in this market are Abbott Laboratories (U.S.), GE Health care (U.K.), Johnson & Johnson, Inc. (U.S.), Covidien (Ireland), Mindray Medical (China), Philips Healthcare (Netherlands), Drager Medical GmbH (Germany), and Roche Diagnostics Limited (Switzerland). Key Topics Covered: 1 Executive Summary 2 Introduction 3 Market Analysis 4 Global Patient Monitoring System Market, By Device 5 Global Patient Monitoring System Market, By End-Users 6 Regional Market Analysis 7 Company Developments 8 Major Company Profiles - Abbott Laboratories - Boston Scientific Corpoartion - Covidien Plc - Ge Healthcare - Johnson & Johnson - Medtronic Inc. - Omron Healthcare, Inc. - Philips Healthcare - Roche Ltd. - St. Jude Medical, Inc. Visit http://www.researchandmarkets.com/research/vvvf8m/patient
BSX: 14.98 (+0.24), JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), STJ: 67.48 (+0.65)
RBCC Joint Venture Partner n3D to Present Latest 3D Bioprinting Research in Washington, D.C.
Business Wire - Tue Feb 10, 4:00AM CST
Rainbow Coral Corp.'s (OTCBB:RBCC) 3D bioprinting joint venture partner Nano3D Biosciences (n3D) will present a new abstract detailing the latest breakthroughs made using its technology in Washington, D.C. on Wednesday at the 4th annual Society for Laboratory Automation and Screening Conference and Exhibition (SLAS2015).
ABT: 46.09 (+0.87), BIIB: 391.66 (-0.45), AMGN: 153.48 (+0.30)
Abbott Laboratories Falls 2.15% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Feb 09, 4:06PM CST
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $44.30 to a high of $45.21. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $45.05 on volume of 6.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ABT: 46.09 (+0.87)
Research and Markets: Active Pharmaceutical Ingredients (API) Market in the US 2015-2019 with Abbott Laboratories, Aurobindo Pharma, Mylan & Teva Pharmaceutical Industries Dominating
Business Wire - Mon Feb 09, 1:13PM CST
Research and Markets (http://www.researchandmarkets.com/research/l6vx9x/active) has announced the addition of the "Active Pharmaceutical Ingredients (API) Market in the US 2015-2019" report to their offering.
ABT: 46.09 (+0.87), TEVA: 56.77 (-0.58)
Active Pharmaceutical Ingredients (API) Market in the US 2015-2019 with Abbott Laboratories, Aurobindo Pharma, Mylan & Teva Pharmaceutical Industries Dominating
M2 - Mon Feb 09, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/jgfvvc/active) has announced the addition of the "Active Pharmaceutical Ingredients (API) Market in the US 2015-2019" report to their offering. The API market in the US to grow at a CAGR of 7% over the period 2014-2019 Active pharmaceutical ingredients (API) are active substances that are used in the manufacture of drugs and that have pharmacological effects. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. API may be synthesized either chemically or through biotechnological methods. They are used in a wide range of therapeutic areas such as oncology and for treatment of conditions such as respiratory disorders and rheumatoid arthritis. One major trend upcoming in the market is the strong focus on the development and introduction of high-potency API. Such products are increasingly used in oncology and for the provision of targeted therapy. According to the report, one of the key drivers contributing to the growth of the API market in the US is the strong preference for generic drugs compared with innovative or branded drugs. The use of generic equivalents is preferred to innovative drugs, with countries encouraging doctors and pharmacists to prescribe such equivalents. Further, the report states that stringent regulationse one of the major challenges that the market faces. Vendors are required to comply with elaborate procedures prior to product commercialization. For instance, compliance with GMP requirements increases costs for vendors. Key Vendors - Abbott Laboratories - Aurobindo Pharma - Mylan - Teva Pharmaceutical Industries Other Prominent Vendors - Albemarle - Aptuit - BASF - Biocon - Boehringer Ingelheim - Cambrex - Cipla - Dr. Reddy's Laboratories - Hospira - Lonza Group - Novartis - Pfizer - Sigma-Aldrich - Sun Pharmaceutical Industries Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - API Market in the US - Market Segmentation by Type of Production Process - Market Segmentation by Type of Product - Market Segmentation by Type of Players - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/jgfvvc/active
ABT: 46.09 (+0.87), CBM: 32.96 (+0.09), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Jim Cramer on the Stock Market: Spinoffs Are in Vogue
at The Street - Mon Feb 09, 8:16AM CST
The logic of owning the pure play is attractive.
HYH: 44.50 (+0.52), HRS: 77.73 (+0.42), XLS: 24.15 (+0.04), ABT: 46.09 (+0.87), BDX: 143.71 (+0.72), CFN: 59.81 (+0.01), CAH: 86.08 (+0.04), PFE: 34.64 (-0.23), KMB: 111.00 (+0.82), ITT: 41.93 (+2.51), TWTR: 48.50 (+0.55), HSP: 87.35 (unch)
Abbott Looks Forward To Another Strong Year
Valuentum - at Seeking Alpha - Mon Feb 09, 7:15AM CST
ABT: 46.09 (+0.87)
Europe Medical Device Market Outlook to 2018 - Driven by the Presence of Advanced Healthcare Industry and Ageing Population
M2 - Mon Feb 09, 6:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/scd2nc/europe_medical) has announced the addition of the "Europe Medical Device Market Outlook to 2018 - Driven by the Presence of Advanced Healthcare Industry and Ageing Population" report to their offering. The report titled Europe Medical Device Market Outlook to 2018 - Driven by the Presence of Advanced Healthcare Industry and Ageing Population presents a comprehensive analysis of the industry aspects including market size by production value of medical devices market in Europe. The report also entails market share analysis and company profiles of major players operating in the medical devices market in Europe. The medical device market of Europe is mainly comprised of medical equipments such as consumables, orthopaedic devices, dental devices, respiratory devices, and ophthalmic devices which are manufactured in Germany, France, the UK, Italy and Spain. The future analysis, trends and developments, government regulations and segmentation by application have also been discussed in the industry research report. The demand for medical devices has been growing owing to a mounting awareness for early diagnosis and treatment of countless disease states in European countries. Other factors propelling the escalating demand for medical devices are the ageing populace, growth in the number of better informed patients and the accessibility of enhanced technologies. In the recent years, medical devices industry in Europe has witnessed a continuous growth. The key countries that have contributed significantly to the Europe medical devices market during 2008-2013 include Germany, UK and France. Germany is one of the major European markets and it has been observed that the country contributes immensely to the exports of medical devices. An increased investment in R&D on healthcare has played a fundamental role in the economic growth of Germany as it has resulted in improved health outcomes and extended years of life. Key Topics Covered: 1. Europe Medical Devices Market Introduction 2. Europe Medical Devices Market Size, 2008-2013 3. Europe Medical Devices Market Segmentation 4. Europe Medical Device Market- Key Drivers 5. Trade Channel of Medical Devices in Europe 6. Trends in Europe Medical Devices Market 7. Mergers and Acquisitions in Medical Devices Market 8. Germany Medical Devices Market 9. France Medical Devices Market 10. The UK Medical Devices Market 11. Italy Medical Devices Market 12. Spain Medical Devices Market 13. Company Profiles of Major Players in Europe Medical Device Market 14. Europe Medical Device Market Future Outlook and Projections, 2014-2018 15. Appendix Companies Mentioned - Abbott Laboratories Limited - Air Liquide Sante - B Braun - Baxter - Drager Medical - Fresenius - GE Healthcare Ltd - Johnson and Johnson - Otto Bock - Philips Healthcare - Siemens Medical - Smith & Nephew - Toshiba Healthcare For more information visit http://www.researchandmarkets.com/research/sc...pe_medical
SNN: 35.82 (-0.28), JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87)
SmarTrend Watching for Potential Pullback in Shares of Abbott Laboratories After 1.92% Gain
Comtex SmarTrend(R) - Fri Feb 13, 3:54PM CST
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $45.02 to a high of $46.17. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $45.25 on volume of 6.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ABT: 46.09 (+0.87)
3 Health Care Stocks On The Rise
at The Street - Fri Feb 13, 11:04AM CST
TheStreet highlights 3 stocks pushing the health care sector higher today.
ABT: 46.09 (+0.87), ALXN: 182.29 (+6.02), ABBV: 58.05 (+1.00)
$173 Billion Wearable Technology Market Report 2015-2020 - Analysis of 221 Companies Offering 132 Different Wearable Technology Products
M2 - Thu Feb 12, 6:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/pwzm38/wearable) has announced the addition of the "Wearable Technology: 2015" report to their offering. Wearable technology will be worth USD 22.7 billion in 2015 rising to USD 173.3 billion by 2020, but the long-term potential of the sector will make these numbers seem rather small. The wearable technology market currently contains the following product segments: body sensors, smart watches, smart glasses, personal video recorders, electronic apparel and jewellery. These products are being used for the following purposes: health and activity tracking, sports performance monitors, wearable web, healthcare, life logging, location tracking and fashion and protective apparel. All these segments are included in this report. The report includes forecasts from 2014 to 2020 for smart watches, smart glasses, fitness and activity trackers and sports performance monitors. You will find very clear and detailed explanations of these and a wide range of other segments of the wearable technology market - plus plenty of examples of companies and products that occupy each of these segments. This report also contains a detailed review and status report for the main enabling technologies that will take the wearables market to the next level: ECG, body power, multi-function earbuds, thought control, electronic contact lenses and bio sensors (ingestibles and implants). You will also be able to read a very clear and detailed analysis of the future direction of the wearable technology market which will see the sector evolve from a largely device-focused industry into something far larger and more exciting. Key Topics Covered: 1. Executive Summary 2. Introduction: Market Segmentation 3. Market Developments: Last 12 Months 4. Wearable Technology Company Profiles 5. Future: Important Enabling Technologies 6. Market Analysis 7. Two $1 Trillion Wearables Opportunities 8. Market Forecasts Companies Mentioned - Abbott Laboratories - Adidas - Apple Watch - Casio - Ezio - FiLIP Technologies - Fitbit - Fitbug - Garmin - Google - Huawei B1 TalkBand - Intel - Jawbone - LG - Lenovo - Medtronic - Microsoft - Misfit Wearables - Motorola Mobility - Nike - Nissan - Omega Wave - Pebble - Pivothead - Polar - Qualcomm - Samsung - Sony - TomTom For more information visit http://www.researchandmarkets.com/research/pwzm38/wearable
ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), QCOM: 70.88 (+0.49), GRMN: 55.93 (+0.02)
Global In-Vitro Diagnostics (IVD) Market Report: 2014 Edition
M2 - Wed Feb 11, 2:14PM CST
Research and Markets (http://www.researchandmarkets.com/research/62bj7n/global_invitro) has announced the addition of the "Global In-Vitro Diagnostics (IVD) Market Report: 2014 Edition" report to their offering. An in-vitro diagnostic test is performed outside of a human body in an artificial environment (e.g. laboratory). IVD is considered as an essential part of today's healthcare. The IVD products are broadly divided into three categories: reagents, analytical instruments and accessory products. IVD is widely used for diagnosis, monitoring of prescribed treatments and assessment of medical intervention, apart from others thereby contributing to availability of medical information regarding a patient. Furthermore, IVD allows earlier and more targeted treatment which in turn leads to reduced hospital stays and convalescences resulting in a healthier population and economic growth in the long run. The key factors which are anticipated to drive market growth include rising global healthcare expense, increasing global ageing population, accelerating global diabetic population apart from rising incidences of chronic and infectious diseases and increasing global gross national income. Some of the noteworthy developments of this industry include food safety testing market being taken over, development in patient monitoring and telemedicine, continued expansion of POC testing apart from mergers and acquisitions. However, the industry remains threatened by certain challenges which include lack of economies of scale and scope, increase in investment demands apart from usual regulatory, reimbursement and intellectual property issues. This report offers a comprehensive analysis of the global in-vitro diagnostic market, along with an in-depth study of the IVD segments and the regional markets of Europe and China. The global IVD industry is consolidated with the top players, Abbott, Siemens, Roche and Johnson and Johnson which operate in a highly competitive environment. The above mentioned companies are being profiled along with their key financials and strategies for growth. Key Topics Covered: 1. Overview 2. IVD Market Size 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Featured: - Abbott Laboratories - Siemens AG - Roche Holdings AG - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/62...al_invitro
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87)
Global Glucose Monitoring Market Report: 2015 Edition
M2 - Wed Feb 11, 10:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/q2z5b6/global_glucose) has announced the addition of the "Global Glucose Monitoring Market Report: 2015 Edition" report to their offering. The key factors which are anticipated to drive the market include factors like increasing aging population, rising healthcare expenditure, increasing urbanization, obese population and awareness about blood glucose monitoring. Some of the noteworthy developments of this industry include sedentary lifestyle, increasing prevalence of diabetes, among others. However, the growth of respective industry is hindered by the barriers of regulatory risk, intense competition, and non-invasive blood glucose monitoring, among others. This report offers a comprehensive analysis of the global glucose monitoring industry. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. On the contention front, the global glucose monitoring market is reined by few major players namely, Johnson and Johnson, Bayer, Roche and Abbott. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail. Key Topics Covered: 1. Introduction 2. Market Analysis 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Featured: - Johnson and Johnson - Abbott Laboratories - Roche Holdings AG - Bayer AG For more information visit http://www.researchandmarkets.com/research/q2...al_glucose
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87)
Zoetis Beats on Q4 Earnings, Provides In-Line 2015 Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 11, 9:56AM CST
Zoetis' fourth-quarter 2014 adjusted earnings of 40 cents per share were ahead of the Zacks Consensus Estimate.
ZTS: 45.46 (-0.33), ABT: 46.09 (+0.87), ALNY: 95.54 (+1.67), ACHN: 10.89 (-0.20)
Global Insulin Delivery Devices Market 2014-2018: Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co Account for 90% of Global Share
M2 - Wed Feb 11, 9:17AM CST
Research and Markets (http://www.researchandmarkets.com/research/hjxrhm/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering. This study thus leads to the proposition that innovation has huge scope in the field of insulin delivery and its analysts have elaborate information on some of the emerging insulin delivery devices. Finally, an analysis of the leading market players provides a holistic understanding to the reader. Players covered include Novo Nordisk, Eli Lilly, Sanofi-Aventis, Medtronic, Roche and Becton, and Dickinson and Co. These players together account for more than 90% of the global market. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Global Insulin Market Overview to 2018 4. Industry Trends and Drivers 5. Key Market Restraints 6. Global Insulin Delivery Devices Market Outlook to 2018 7. Insulin Delivery Devices: Current and Future Outlook to 2018 8. Emerging Devices 9. Key Players - Abbott Laboratories - B. Braun Melsungen AG - Becton Dickinson - Eli Lilly - F. Hoffmann La Roche - Insulet Corporation - Johnson and Johnson - Medtronic - Novo Nordisk - Sanofi-Aventis - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/hj...al_insulin
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), PODD: 32.00 (-0.07), NVO: 43.76 (+0.61), MDT: 75.26 (+0.33), LLY: 70.56 (+0.03)
Analyzing the Global Pharmaceutical Industry 2015
M2 - Wed Feb 11, 8:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/jvx6qs/analyzing_the) has announced the addition of the "Analyzing the Global Pharmaceutical Industry 2015" report to their offering. This report presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018. The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy - store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat. We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry. An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. Key Topics Covered: Section 1: Analyzing the Global Pharmaceutical Industry Section 2: Analyzing the Global Pharmaceutical Markets Section 3: Analyzing the Major Market Players Section 4: Glossary of Terms Companies Mentioned - Abbott Laboratories - Allergan, Inc. - Amgen, Inc. - Astellas Pharma - AstraZeneca - Aurobindo Pharma Ltd - Baxter International - Bayer AG - Boehringer Ingelheim - Bristol-Myers Squibb - Cadila Healthcare - Chiesi Farmaceutici SpA - Dr. Reddy's Laboratories Limited - Eisai Co., Ltd - Eli Lilly and Company - F. Hoffmann-La Roche - GlaxoSmithKline Plc - Jiangsu Yangtze River Pharmaceutical Group Co., Ltd. - Johnson & Johnson - Jubilant Life Sciences Ltd - Lupin Limited - Merck & Co. - Mylan Laboratories Ltd - Novartis AG - Pfizer - Sanofi SA - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries - Yunnan Baiyao Group For more information visit http://www.researchandmarkets.com/research/jv...lyzing_the About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), BAX: 70.39 (+0.31), MRK: 58.81 (-0.07), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Global Digital PCR (dPCR) Market 2015-2019: Key Vendors are Bio-Rad Laboratories, Fluidigm, RainDance Technologies & Thermo Fisher Scientific
M2 - Wed Feb 11, 6:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/gqxfbj/global_digital) has announced the addition of the "Global Digital PCR (dPCR) Market 2015-2019" report to their offering. The Global dPCR market to grow at a CAGR of 26.45% over the period 2014-2019 The dPCR technology is an innovative PCR that allows amplification and directs quantification of nucleic acids such as DNA, RNA, cDNA, and methylated DNA with high precision. The dPCR technology is not dependent on the number of amplification cycles to quantify the initial sample amount and provides absolute quantification of nucleic acids. dPCR can analyze a small amount of sample and provide higher accuracy, precision, and efficiency than the conventional PCR technology. The adoption of dPCR technology is a major trend upcoming in this market. Advanced dPCR technology and products provide a high degree of accuracy and productivity in research and drug discovery and reduce the consumption of reagents. According to the report, one of the major drivers of the market is advances in dPCR technology. dPCR technologies and products have improved because of automation, accuracy, sensitivity, and ease of handling. In addition, advanced dPCR products provide greater efficiency and productivity in research and drug discovery and help reduce the time taken for the development of new drugs. Further, the report states that availability of alternative technologies is a major challenge that the market faces. Availability of other sequencing technologies such as other PCR techniques and NGS poses a serious threat to the adoption of dPCR technology. The dPCR technologies have a broad range of applications in various fields including: - Drug discovery and development - Clinical diagnostics - Research - Others Key Vendors - Bio-Rad Laboratories - Fluidigm - RainDance Technologies - Thermo Fisher Scientific Other Prominent Vendors - Abbott Laboratories - Affymetrix - Analytik Jena - ArcticZymes - Becton Dickinson - Bibby Scientific - bioMerieux - Biosearch Technologies - BIOTECON Diagnostics - Eppendorf - Exiqon - Formulatrix - Illumina - Integrated DNA Technologies - Promega - Sigma-Aldrich - Stilla Technologies For more information visit http://www.researchandmarkets.com/research/gq...al_digital
ABT: 46.09 (+0.87)
Sports and Fitness Nutrition Supplements - Global Strategic Business Report 2015
M2 - Wed Feb 11, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/kzpfhr/sports_and) has announced the addition of the "Sports and Fitness Nutrition Supplements - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Sports and Fitness Nutrition Supplements in US$ Thousands by the following Segments: - Amino Acids/Derivatives - Herbal Products - Vitamins/Minerals - Others Company profiles are primarily based on public domain information including company URLs. The report profiles 237 companies including many key and niche players such as: - Abbott Laboratories Inc. (US) - Champion Nutrition, Inc. (US) - Clif Bar & Company (US) - Dymatize Enterprises, Inc. (US) - Glanbia Plc (Ireland) - Optimum Nutrition, Inc. (US) - GlaxoSmithKline Plc (UK) - GNC Holdings, Inc. (US) - Herbalife International, Inc. (US) - NBTY, Inc. (US) - The Balance Bar Company (US) - Nestl? SA (Switzerland) - Otsuka Pharmaceutical Co., Ltd. (Japan) - PepsiCo Inc. (US) - Red Bull GmbH (Austria) - The Coca-Cola Co. (US) - Yakult Honsha Co., Ltd. (Japan) Key Topics Covered: 1. INDUSTRY OVERVIEW 2. MARKET DYNAMICS 3. TRENDS AND ISSUES 4. PRODUCT INNOVATIONS: A CLOSER LOOK 5. PRODUCT OVERVIEW 6. PRODUCT INTRODUCTIONS/LAUNCHES 7. RECENT INDUSTRY ACTIVITY 8. FOCUS ON SELECT GLOBAL PLAYERS 9. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 237 (including Divisions/Subsidiaries 253) - The United States (173) - Canada (9) - Japan (3) - Europe (48) - France (2) - Germany (2) - The United Kingdom (30) - Rest of Europe (14) - Asia-Pacific (Excluding Japan) (15) - Latin America (1) - Africa (4) For more information visit http://www.researchandmarkets.com/research/kzpfhr/sports_and
HLF: 32.78 (-0.84), ABT: 46.09 (+0.87), GSK: 47.94 (+1.99), PEP: 99.13 (-1.14)
Mylan Faces Patent Infringement Lawsuit for Nexavar - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 2:02PM CST
Mylan (MYL) confirms patent challenge for generic version of Nexavar, and it expects exclusivity.
IPXL: 39.51 (+0.69), ABT: 46.09 (+0.87), MYL: 55.85 (+1.34)
Pfizer Pays A Pretty Penny For Hospira: Here's What You Need To Know
Brendan O'Boyle - at Seeking Alpha - Tue Feb 10, 8:49AM CST
ABT: 46.09 (+0.87), TARO: 161.14 (-1.44), PFE: 34.64 (-0.23), MYL: 55.85 (+1.34), EPRS: 7.67 (+0.67), TEVA: 56.77 (-0.58), HSP: 87.35 (unch)
Patient Monitoring Global Market 2015 - Forecast to 2020
M2 - Tue Feb 10, 8:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/vvvf8m/patient) has announced the addition of the "Patient Monitoring Global Market - Forecast to 2020" report to their offering. The global patient monitoring devices market is expected to reach approximately $24 billion by 2019 growing at CAGR of around 8.0%. North America commands the largest share and is expected to register a healthy market share by 2019. APAC is going to be one of the prominent regions for this market in coming years driven by the increased purchasing power and rising population. Patient monitoring is essential part of care process together with administration of therapy. The main aim of monitoring is to make sure that proper care [or] therapy can be given in advance to the arrival of complications. Patient monitoring is essential to take care in emergency and operating rooms, intensive and critical care units and it is extremely useful for recovery rooms, respiration therapy, radiology, outpatient care, and gastroenterology department, Transport, Home and sleep screening applications. Patient monitoring play key role to reduce complications, risks, infections as well assist in providing for patient comfort. Patient monitoring devices market is mainly divided into following segments such as Hemodynamic, neurology, respiratory, Cardiology, fetal and neonatal, multi parameters, remote patient monitors, temperature and weight monitors. Some of the key players in this market are Abbott Laboratories (U.S.), GE Health care (U.K.), Johnson & Johnson, Inc. (U.S.), Covidien (Ireland), Mindray Medical (China), Philips Healthcare (Netherlands), Drager Medical GmbH (Germany), and Roche Diagnostics Limited (Switzerland). Key Topics Covered: 1 Executive Summary 2 Introduction 3 Market Analysis 4 Global Patient Monitoring System Market, By Device 5 Global Patient Monitoring System Market, By End-Users 6 Regional Market Analysis 7 Company Developments 8 Major Company Profiles - Abbott Laboratories - Boston Scientific Corpoartion - Covidien Plc - Ge Healthcare - Johnson & Johnson - Medtronic Inc. - Omron Healthcare, Inc. - Philips Healthcare - Roche Ltd. - St. Jude Medical, Inc. Visit http://www.researchandmarkets.com/research/vvvf8m/patient
BSX: 14.98 (+0.24), JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), STJ: 67.48 (+0.65)
RBCC Joint Venture Partner n3D to Present Latest 3D Bioprinting Research in Washington, D.C.
Business Wire - Tue Feb 10, 4:00AM CST
Rainbow Coral Corp.'s (OTCBB:RBCC) 3D bioprinting joint venture partner Nano3D Biosciences (n3D) will present a new abstract detailing the latest breakthroughs made using its technology in Washington, D.C. on Wednesday at the 4th annual Society for Laboratory Automation and Screening Conference and Exhibition (SLAS2015).
ABT: 46.09 (+0.87), BIIB: 391.66 (-0.45), AMGN: 153.48 (+0.30)
Abbott Laboratories Falls 2.15% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Feb 09, 4:06PM CST
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $44.30 to a high of $45.21. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $45.05 on volume of 6.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ABT: 46.09 (+0.87)
Research and Markets: Active Pharmaceutical Ingredients (API) Market in the US 2015-2019 with Abbott Laboratories, Aurobindo Pharma, Mylan & Teva Pharmaceutical Industries Dominating
Business Wire - Mon Feb 09, 1:13PM CST
Research and Markets (http://www.researchandmarkets.com/research/l6vx9x/active) has announced the addition of the "Active Pharmaceutical Ingredients (API) Market in the US 2015-2019" report to their offering.
ABT: 46.09 (+0.87), TEVA: 56.77 (-0.58)
Active Pharmaceutical Ingredients (API) Market in the US 2015-2019 with Abbott Laboratories, Aurobindo Pharma, Mylan & Teva Pharmaceutical Industries Dominating
M2 - Mon Feb 09, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/jgfvvc/active) has announced the addition of the "Active Pharmaceutical Ingredients (API) Market in the US 2015-2019" report to their offering. The API market in the US to grow at a CAGR of 7% over the period 2014-2019 Active pharmaceutical ingredients (API) are active substances that are used in the manufacture of drugs and that have pharmacological effects. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. API may be synthesized either chemically or through biotechnological methods. They are used in a wide range of therapeutic areas such as oncology and for treatment of conditions such as respiratory disorders and rheumatoid arthritis. One major trend upcoming in the market is the strong focus on the development and introduction of high-potency API. Such products are increasingly used in oncology and for the provision of targeted therapy. According to the report, one of the key drivers contributing to the growth of the API market in the US is the strong preference for generic drugs compared with innovative or branded drugs. The use of generic equivalents is preferred to innovative drugs, with countries encouraging doctors and pharmacists to prescribe such equivalents. Further, the report states that stringent regulationse one of the major challenges that the market faces. Vendors are required to comply with elaborate procedures prior to product commercialization. For instance, compliance with GMP requirements increases costs for vendors. Key Vendors - Abbott Laboratories - Aurobindo Pharma - Mylan - Teva Pharmaceutical Industries Other Prominent Vendors - Albemarle - Aptuit - BASF - Biocon - Boehringer Ingelheim - Cambrex - Cipla - Dr. Reddy's Laboratories - Hospira - Lonza Group - Novartis - Pfizer - Sigma-Aldrich - Sun Pharmaceutical Industries Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - API Market in the US - Market Segmentation by Type of Production Process - Market Segmentation by Type of Product - Market Segmentation by Type of Players - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/jgfvvc/active
ABT: 46.09 (+0.87), CBM: 32.96 (+0.09), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Jim Cramer on the Stock Market: Spinoffs Are in Vogue
at The Street - Mon Feb 09, 8:16AM CST
The logic of owning the pure play is attractive.
HYH: 44.50 (+0.52), HRS: 77.73 (+0.42), XLS: 24.15 (+0.04), ABT: 46.09 (+0.87), BDX: 143.71 (+0.72), CFN: 59.81 (+0.01), CAH: 86.08 (+0.04), PFE: 34.64 (-0.23), KMB: 111.00 (+0.82), ITT: 41.93 (+2.51), TWTR: 48.50 (+0.55), HSP: 87.35 (unch)
Abbott Looks Forward To Another Strong Year
Valuentum - at Seeking Alpha - Mon Feb 09, 7:15AM CST
ABT: 46.09 (+0.87)
Europe Medical Device Market Outlook to 2018 - Driven by the Presence of Advanced Healthcare Industry and Ageing Population
M2 - Mon Feb 09, 6:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/scd2nc/europe_medical) has announced the addition of the "Europe Medical Device Market Outlook to 2018 - Driven by the Presence of Advanced Healthcare Industry and Ageing Population" report to their offering. The report titled Europe Medical Device Market Outlook to 2018 - Driven by the Presence of Advanced Healthcare Industry and Ageing Population presents a comprehensive analysis of the industry aspects including market size by production value of medical devices market in Europe. The report also entails market share analysis and company profiles of major players operating in the medical devices market in Europe. The medical device market of Europe is mainly comprised of medical equipments such as consumables, orthopaedic devices, dental devices, respiratory devices, and ophthalmic devices which are manufactured in Germany, France, the UK, Italy and Spain. The future analysis, trends and developments, government regulations and segmentation by application have also been discussed in the industry research report. The demand for medical devices has been growing owing to a mounting awareness for early diagnosis and treatment of countless disease states in European countries. Other factors propelling the escalating demand for medical devices are the ageing populace, growth in the number of better informed patients and the accessibility of enhanced technologies. In the recent years, medical devices industry in Europe has witnessed a continuous growth. The key countries that have contributed significantly to the Europe medical devices market during 2008-2013 include Germany, UK and France. Germany is one of the major European markets and it has been observed that the country contributes immensely to the exports of medical devices. An increased investment in R&D on healthcare has played a fundamental role in the economic growth of Germany as it has resulted in improved health outcomes and extended years of life. Key Topics Covered: 1. Europe Medical Devices Market Introduction 2. Europe Medical Devices Market Size, 2008-2013 3. Europe Medical Devices Market Segmentation 4. Europe Medical Device Market- Key Drivers 5. Trade Channel of Medical Devices in Europe 6. Trends in Europe Medical Devices Market 7. Mergers and Acquisitions in Medical Devices Market 8. Germany Medical Devices Market 9. France Medical Devices Market 10. The UK Medical Devices Market 11. Italy Medical Devices Market 12. Spain Medical Devices Market 13. Company Profiles of Major Players in Europe Medical Device Market 14. Europe Medical Device Market Future Outlook and Projections, 2014-2018 15. Appendix Companies Mentioned - Abbott Laboratories Limited - Air Liquide Sante - B Braun - Baxter - Drager Medical - Fresenius - GE Healthcare Ltd - Johnson and Johnson - Otto Bock - Philips Healthcare - Siemens Medical - Smith & Nephew - Toshiba Healthcare For more information visit http://www.researchandmarkets.com/research/sc...pe_medical
SNN: 35.82 (-0.28), JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87)
